The prescription use of stimulants such as Ritalin and Adderall (methylphenidate and amphetamine, respectively) for the treatment of ADHD has been increasing. In 2007, the FDA mandated changes to drug labels for stimulants, based on findings about increased risk for psychosis. We studied whether the risk of psychosis in patients with ADHD differs among various stimulant types and found that patients prescribed amphetamine were at a higher risk of new psychosis requiring treatment with antipsychotic medicines than patients who had been prescribed methylphenidate.
Watch webinar recording:
Please use #BBRFWebinar when sharing or posting about our Meet the Scientist Webinars on social media.